Key result
PVSRIPO tumor cell toxicity relies on MNK-controlled suppression of mTORC2-AKT signaling, which attenuates SRPK activity to enhance viral translation and oncolysis.
The oncolytic immunotherapy PVSRIPO relies on ERK1/2-MNK signals that counteract AKT-SRPK activity to achieve tumor-selective translation and cytotoxicity.
PVSRIPO tumor cytotoxicity facilitated by Raf-ERK1/2 signals; leaves open clinical translation in oncology.
UNLABELLED: Translation machinery is a major recipient of the principal mitogenic signaling networks involving Raf-ERK1/2 and phosphoinositol 3-kinase (PI3K)-mechanistic target of rapamycin (mTOR). Picornavirus internal ribosomal entry site (IRES)-mediated translation and cytopathogenic effects are susceptible to the status of such signaling cascades in host cells. We determined that tumor-specific cytotoxicity of the poliovirus/rhinovirus chimera PVSRIPO is facilitated by Raf-ERK1/2 signals to the mitogen-activated protein kinase (MAPK)-interacting kinase (MNK) and its effects on the partitioning/activity of the Ser/Arg (SR)-rich protein kinase (SRPK) (M. C. Brown, J. D. Bryant, E. Y. Dobrikova, M. Shveygert, S. S. Bradrick, V. Chandramohan, D. D. Bigner, and M, Gromeier, J. Virol. 22:13135-13148, 2014, doi:http://dx.doi.org/10.1128/JVI.01883-14). Here, we show that MNK regulates SRPK via mTOR and AKT. Our investigations revealed a MNK-controlled mechanism acting on mTORC2-AKT. The resulting suppression of AKT signaling attenuates SRPK activity to enhance picornavirus type 1 IRES translation and favor PVSRIPO tumor cell toxicity and killing. IMPORTANCE: Oncolytic immunotherapy with PVSRIPO, the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine containing a human rhinovirus type 2 (HRV2) IRES, is demonstrating early promise in clinical trials with intratumoral infusion in recurrent glioblastoma (GBM). Our investigations demonstrate that the core mechanistic principle of PVSRIPO, tumor-selective translation and cytotoxicity, relies on constitutive ERK1/2-MNK signals that counteract the deleterious effects of runaway AKT-SRPK activity in malignancy.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2014) studied Glioblastoma. PVSRIPO was evaluated on Tumor cell toxicity and killing. PVSRIPO tumor cell toxicity relies on MNK-controlled suppression of mTORC2-AKT signaling, which attenuates SRPK activity to enhance viral translation and oncolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Journal of Virology